Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.33 |
| ▸ | PLCG1 | P19174 | 1/20 | 0.33 |
| ▸ | ELANE | P08246 | 3/20 | 0.32 |
| ▸ | RAB9A | P51151 | 2/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.31 |
| ▸ | HTR2A | P28223 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7722352 | 0.93 | PLCG1 (0.38) | L3MBTL1PLCG1ELANERAB9AHTT | |
| SCHEMBL5233536 | 0.89 | PLCG1 (0.32) | PLCG1ELANEHTTHTR2A | |
| SCHEMBL7041829 | 0.88 | PLCG1 (0.35) | L3MBTL1PLCG1ELANEHTTHTR2A | |
| SCHEMBL7728957 | 0.88 | PLCG1 (0.37) | MAPTL3MBTL1PLCG1ELANEHTT | |
| SCHEMBL7730230 | 0.88 | PLCG1 (0.35) | L3MBTL1PLCG1ELANERAB9AHTT | |
| SCHEMBL7728647 | 0.88 | ELANE (0.36) | L3MBTL1PLCG1ELANEHTTHTR2A | |
| SCHEMBL7730458 | 0.88 | PLCG1 (0.35) | L3MBTL1PLCG1ELANERAB9AHTT | |
| SCHEMBL7722446 | 0.88 | ELANE (0.36) | L3MBTL1PLCG1ELANEHTTHTR2A | |
| SCHEMBL7003427 | 0.88 | RAB9A (0.36) | L3MBTL1PLCG1ELANERAB9AKMT2A | |
| SCHEMBL7631759 | 0.87 | PLCG1 (0.36) | L3MBTL1PLCG1ELANEHTTHTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090082571-A1 | Intermediates of 2-substituted carbapenem derivatives and process for production thereof | SASAKI TOSHIRO | 2009-03-26 | — | — | US | disclosed |
| EP-1582522-A1 | INTERMEDIATE FOR 2-SUBSTITUTED CARBAPENEM DERIVATIVE AND PRODUCTION PROCESS | MEIJI SEIKA KAISHA LTD. (JP) | 2005-10-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090082571-A1 | Intermediates of 2-substituted carbapenem derivatives and process for production thereof | MGAM, G6PD, COASY | MAPT 4112/4885L3MBTL1 3309/4885PLCG1 2811/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.